Search Results
Your search for ,aGe matches 8736 pages
Showing 151 - 200ACS Guidelines for Cervical Cancer
Self-collection of vaginal samples for human papillomavirus (HPV) testing is now being considered an acceptable, recommended option for cervical cancer screening, per recent updates to the American Cancer Society’s (ACS) guidelines published in CA: A Cancer Journal for Clinicians. Another...
Cancer Mortality According to Occupation in the United States
In a study reported in The Lancet Oncology, Lesinski et al identified cancer mortality rates according to the occupation of U.S. adults aged 20 to 64 years between 2020 and 2023. Study Details The study used information on cancer deaths for 22 main cancer sites from 2020 to 2023 among adults aged...
Study Finds GLP-1 RAs May Influence Colorectal Cancer Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting ...
Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRI
New results from the BREAKWATER trial show that the targeted therapy combination of encorafenib and cetuximab with the chemotherapy fluorouracil, folinic acid, and irinotecan (FOLFIRI) can reduce the size or number of tumors in patients with BRAF V600E–mutant metastatic colorectal cancer. Adding...
AI-Based Imaging Model Predicts Extranodal Extension Burden and Improves Risk Stratification in Oropharyngeal Cancer
Prediction of the number of lymph nodes with extranodal extension in patients with oropharyngeal carcinoma through a deep learning imaging platform for autosegmentation may help to guide pretreatment patient risk stratification and treatment decision-making, according to the results of a multisite, ...
High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer
Studies show that while the overall rates of colorectal cancer are decreasing, for individuals younger than age 50, the incidence has risen by an alarming 50% since the mid-1990s. While the exact causes are unknown, poor diet and alcohol consumption are believed to be contributing factors. A study...
Most People Trust AI Less Than Physicians, Survey Finds
Two national surveys examining trust and acceptance of medical artificial intelligence (AI) have found that while most people are reluctant to use AI tools to diagnose their health condition, they see potential in the technology’s ability to help diagnose cancer. The findings, published by Sobolev...
HCC: Real-World Patterns of Systemic Therapy, Sequencing, and Survival
A recent retrospective cohort study has described the current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for hepatocellular carcinoma (HCC). The findings, which were published by Lau-Min et al in JAMA Network Open, showed that...
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer
In a meta-analysis reported in JAMA Oncology, Zaorsky et al found that longer durations of androgen-deprivation therapy given with definitive radiotherapy were associated with nonlinear relative benefits in patients with localized prostate cancer. Study Details The meta-analysis used...
County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults
The International Agency for Research on Cancer has linked obesity to increases in the development of 13 cancers, including breast, colorectal, kidney, endometrial, thyroid, pancreatic, liver, multiple myeloma, gastric cardia, meningioma, ovarian, esophageal, and gallbladder cancers. Now, a new...
Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe...
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated strong high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual...
Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated a high overall complete response rate in patients with high-risk, bacillus Calmette-Guérin (BCG)-naive non–muscle-invasive bladder cancer with carcinoma in situ, according to early results from Cohort A of the phase II...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder...
Tanning Bed Exposure and Melanoma Risks
Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings published in Science Advances show that individuals who used tanning beds had a 2.85-fold higher risk of...
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
As reported in the Journal of Clinical Oncology, Maurer et al have developed FLIPI24, a modern prognostic model for newly diagnosed follicular lymphoma. As stated by the investigators, “Although most patients with … [follicular lymphoma] can expect an indolent course, progressive lymphoma remains...
Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?
Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the 2025 San Antonio Breast Cancer Symposium (SABCS; Abstract GS3-01)....
Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors
New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alone, while real acupuncture improves objective measures of cognitive performance better than sham...
Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer
Similar recurrence and regional recurrence-free survival rates were observed at 5 years with or without a sentinel lymph node biopsy in patients with clinically node-negative cT1-2 breast cancer treated with breast-conserving therapy, according to findings from the phase III BOOG 2013-08 trial...
Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor-positive,...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed a standard treatment strategy of imatinib plus...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Hear, Hear to ‘Advancing Geriatric Oncology: Where We Have Been and Where We Are Going’
We read with interest the commentary by Stuart Lichtman, MD, FASCO,on “Advancing Geriatric Oncology: Where We Have Been and Where We Are Going,“ in the October 25, 2025 issue of The ASCO Post.1 Dr. Lichtman outlines the challenges in delivering cancer care to the elderly population. Among these...
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
Updated findings from the phase II iMMagine-1 study show that anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, continues to deliver high response rates with a reassuring safety profile. Researchers from The University of Texas ...
ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care
On November 10, 2025, the Department of Health and Human Services announced that the Food and Drug Administration will begin to remove the “black box” warning language related to increased risks of cardiovascular disease, breast cancer, and probable dementia from hormone replacement therapy (HRT)...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Cyclophosphamide-Based Strategy Enables Safe Transplant From Broadly Mismatched Donors
Clinicians have traditionally prioritized high-level human leukocyte antigen (HLA) matching to minimize graft-vs-host disease (GVHD) after hematopoietic cell transplantation (HCT). New data from the ACCESS study, sponsored by the National Marrow Donor Program, indicate that the use of...
New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024, and November 19, 2025
Over the past year (December 2024–November 19, 2025), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers. The new approvals and accelerated approvals are listed below according to the most recent new...
Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy
The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk, with “favorable” cancer-specific survival outcomes in the absence of adjuvant chemotherapy,...
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
A new analysis spanning more than 3 decades of Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) clinical trial data demonstrates that Black patients with acute myeloid leukemia (AML) present with the disease at a significantly younger age and...
Toxicity Concerns for PARP Inhibition Given Concurrently With Adjuvant Radiotherapy for Breast Cancer
Rates of radiotherapy-associated adverse events were considerably higher with the concurrent addition of low doses of the PARP inhibitor olaparib compared with radiotherapy alone in patients with inflammatory breast cancer in the adjuvant setting, according to the results of a toxicity analysis...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
AACR Pediatric Cancer Progress Report Highlights Advances Made, Long-Term Survivorship Challenges, and Persistent Disparities in Care
Although treatment advances in pediatric cancers have resulted in increases in overall 5-year survival for children and adolescents diagnosed with cancer, many pediatric survivors face chronic health conditions as they age, as well as financial, social, and psychological challenges, according to...
Are Glycemic Index and Load Associated With Lung Cancer Risk?
Based on the results of a population-based cohort study published in Annals of Family Medicine by Wang et al, high dietary glycemic index is linked to increased risks of lung cancer, non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), whereas glycemic load is inversely associated ...
Upfront Reduced-Dose Enfortumab Vedotin With Pembrolizumab in First-Line Treatment of Advanced Urothelial Cancer
In a U.S. retrospective cohort study reported in JAMA Oncology, Chow et al found that reduced-dose vs standard upfront enfortumab vedotin-ejfv plus pembrolizumab reduced the risk of enfortumab vedotin treatment interruption in the first-line treatment of patients with advanced urothelial cancer....
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1). “This...
Is Chronic Hepatitis C Infection Associated With Pancreatic Cancer?
A retrospective, national, population-based cohort study of 6.3 million veterans, which was published in JAMA Network Open, found that individuals with chronic hepatitis C virus developed pancreatic ductal adenocarcinoma at younger ages and had a higher risk compared with those without the...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Icahn School of Medicine Family Center for Caregiving Launches Website to Further Reach and Broaden Mission
Allison J. Applebaum, PhD, FAPOS, recently announced the launch of the website for the Steven S. Elbaum Family Center for Caregiving at the Icahn School of Medicine at Mount Sinai in New York (www.mountsinai.org/care/palliative-care/elbaum-center-caregiving). Dr. Applebaum is Director of the...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC
With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic surgery (VATS) for early-stage non–small cell lung cancer (NSCLC). These findings from the revised...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
